Bhale Shweta*, Saxena Vaishali, Bhandari Govind, Mahajan S.C.
Mahakal Institute of Pharmaceutical studies,
Connective tissue disease include the following state: rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, polyarteritis nodosa, gout, rheumatic fever and osteoarthritis, with the most common forms of which are rheumatoid arthritis, osteoporosis and gout. Rheumatoid arthritis is a chronic, nonsuppurative inflammatory disease of unknown cause affecting primarily peripheral synovial joint. the onset is usually insidious, with immunological reaction playing a major role. Common medications for arthritis include nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs decrease pain, inflammation, and fever by blocking cyclo-oxygenase (COX) enzymes. Understanding of the pharmacology of NSAIDs continues to evolve, but it is now thought that most NSAIDs block three different COX isoenzymes, known as COX-1, COX-2, and COX-3. COX-1 protects the lining of the stomach from acid. COX-2 is found in joint and muscle, and mediates effects on pain and inflammation. By blocking COX-2, NSAIDs reduce pain compared to placebo in patients with arthritis, low back pain, minor injuries, and soft tissue rheumatism. selective NSAIDs or “COX-2 selective NSAIDs” as drugs in the “coxib” class (celecoxib, rofecoxib, valdecoxib, etoricoxib, lumiracoxib). “partially selective NSAIDs” as other drugs shown to have partial in vitro COX-2 selectivity (etodolac, nabumetone, meloxicam).